Integer (ITGR) Q1 2025: Cardiovascular Sales Surge 17% as Order Book Nears $800M

April 24, 2025 | By EarningsIQ Research

Integer delivered double-digit margin expansion and cardiovascular outperformance, setting the stage for a CEO transition from strength. With a record order book and disciplined capital allocation, the company is signaling sustained above-market growth and margin leverage. Investors now face a business balancing tariff headwinds, integration of new capabilities, and a maturing growth mix as leadership hands off to a new CEO.

Summary

• Cardiovascular Momentum: Integer’s targeted product launches and acquisitions accelerated growth in the company’s largest segment.
• Margin Expansion: Operational efficiency and business mix drove operating margin gains well ahead of sales growth.
• Strategic Transition: Leadership succession, order visibility, and a robust pipeline underpin confidence in sustained outperformance.

Performance Analysis

Integer’s Q1 2025 results highlight a business leveraging its scale and targeted investments to outpace sector norms. Cardiovascular (C&V), which represents the company’s largest and fastest-growing segment, delivered a standout 17% sales increase, powered by new product ramps in electrophysiology, structural heart, and incremental contributions from the Precision and BSI Paralean acquisitions. This growth was achieved despite a three-point headwind from fewer shipping days, a calendar effect that will partially unwind later in the year.

Operating leverage was a defining feature of the quarter. Adjusted operating income grew at twice the rate of sales, with margin expansion driven by both gross margin improvement (up 70 basis points) and disciplined expense management. Free cash flow improved by $12 million year over year, aided by higher sales, improved margins, and stable capital expenditures. The company’s order book climbed to nearly $800 million, reflecting both robust demand and greater customer visibility as Integer ramps new manufacturing lines for innovative therapies.

• Cardiovascular Outperformance: C&V sales growth outpaced both internal targets and industry averages, reflecting successful execution in high-growth submarkets.
• CRM & Neuromodulation Normalization: Cardiac rhythm management and neuromodulation (CRM&N) grew 2%, reflecting a mix shift toward emerging neuromodulation customers and normalization after prior years’ elevated growth.
• Acquisition Integration: Early contributions from recent tuck-ins were visible in both segment growth and expanded service offerings.

Integer’s results demonstrate its ability to compound organic and inorganic growth while maintaining capital discipline and margin expansion. The company’s global manufacturing footprint, customer concentration, and order visibility remain key levers for sustained performance.

Executive Commentary

Strategic Positioning

1. Cardiovascular Growth Engine

Cardiovascular remains Integer’s primary growth engine, accounting for the largest share of total revenue and outpacing both company and market growth rates. The segment’s 17% sales gain was driven by new product launches in electrophysiology (EP, heart rhythm device technology), structural heart, and renal denervation. Integer’s strategy of targeting high-growth therapy areas and expanding content per procedure is translating to both top-line and margin upside, as evidenced by strong customer adoption and a record order book.

2. Acquisition-Led Capability Expansion

Recent acquisitions, notably Precision Coding and BSI Paralean, have bolstered Integer’s proprietary technology stack and deepened its vertical integration in coatings and materials. These tuck-ins are not only augmenting current product offerings but also positioning Integer as a more strategic partner for OEM customers, who increasingly value differentiated, end-to-end manufacturing capabilities. Integration is progressing smoothly, with early customer engagement and a playbook honed by prior M&A activity.

3. Margin and Cash Flow Discipline

Margin expansion remains a central pillar of Integer’s value creation strategy. The company delivered 100 basis points of operating margin improvement, supported by manufacturing efficiency initiatives and tight expense control. Integer’s capital allocation discipline was further reinforced by a strategic refinancing that fixed more debt at sub-2% rates, reducing interest expense and freeing up revolver capacity for future acquisitions. Free cash flow guidance for the year was raised, reflecting ongoing operational execution.

4. CEO Succession and Culture Continuity

The planned CEO transition from Joe Dziedzic to Payman Kales is framed as a handoff from a position of strength, not necessity. Kales’ track record in the cardiovascular segment and as COO signals continuity in strategy and culture, with a focus on sustaining Integer’s high-performance, customer-centric ethos. The transition is set for October 2025, with Dziedzic remaining as advisor through Q1 2026, providing stability for customers and investors.

5. Resilience to Tariff and Macro Volatility

Integer’s global manufacturing footprint and U.S.-centric supply chain have insulated it from the worst of recent tariff disruptions. Management estimates a $1 to $5 million tariff impact for 2025, with little exposure to China and strong ability to pass through costs. The business is also viewed as recession-resilient, with most therapies supported being non-elective and outsourcing trends continuing to favor Integer’s OEM model.

Key Considerations

Integer’s Q1 performance and guidance reflect a business balancing robust demand, operational leverage, and disciplined capital deployment, yet investors should monitor several evolving dynamics.

Key Considerations:

• Order Book Visibility: The near-$800 million order book offers strong near-term demand confidence, but management expects this to normalize as new product ramps stabilize and the portable medical exit completes.
• CRM & Neuromodulation Growth Mix: The CRM&N segment is transitioning toward a heavier neuromodulation mix, which should support mid-single-digit growth but may introduce margin and execution variability as the customer base diversifies.
• Tariff and Supply Chain Management: Integer’s limited direct exposure to tariffs is a competitive advantage, but second-order effects through suppliers and customer logistics warrant ongoing scrutiny.
• Acquisition Integration and Capital Allocation: The company’s disciplined approach to tuck-in acquisitions and leverage (targeting 2.5–3.5x EBITDA) supports incremental growth, but larger transformative deals remain unlikely under current strategy.
• Leadership Transition Execution: Smooth succession and continuity of strategy are critical as the company navigates both macro uncertainty and evolving customer needs.

Risks

Risks center on execution in integrating recent acquisitions, sustaining above-market organic growth as product mix matures, and managing potential downstream tariff impacts from suppliers. While Integer’s supply chain is currently insulated, any escalation in trade disputes or supplier price increases could pressure margins. Additionally, the normalization of order book levels and CRM&N segment growth could temper the pace of outperformance if not offset by new product launches or further operational gains.

Forward Outlook

For Q2 2025, Integer guided to:

• High single-digit reported sales growth
• Minimal inorganic sales contribution as acquisition gains are offset by portable medical exit

For full-year 2025, management maintained and raised key guidance:

• Sales growth of 8% to 10% reported, 6% to 8% organic
• Adjusted operating income growth of 11% to 16%
• Adjusted EPS of $6.15 to $6.51, up 16% to 23% YoY
• Free cash flow guidance raised by $10 million to $120–$140 million

Management highlighted:

• Order book normalization as new product ramps mature
• Continued focus on margin expansion through efficiency and disciplined SG&A growth

Takeaways

Integer’s Q1 2025 results reinforce its position as a leading OEM partner to medtech innovators, with cardiovascular outperformance, disciplined capital deployment, and a robust order pipeline underpinning the outlook.

• Cardiovascular Outperformance: Targeted investments and product launches are driving sustained growth and share gains in the company’s largest segment.
• Margin and Cash Flow Upside: Operational discipline and strategic refinancing are translating to expanding margins and increased free cash flow outlook.
• Watch for Mix Shifts and Integration: Investors should monitor CRM&N segment growth normalization, order book trends, and the pace of acquisition integration as drivers of future upside or risk.

Conclusion

Integer enters its CEO transition with operational momentum, strong customer visibility, and a proven playbook for both organic and inorganic growth. The company’s focus on high-growth markets, margin discipline, and capital stewardship positions it well, though investors should remain attentive to evolving mix dynamics and macro volatility as the year progresses.

Industry Read-Through

Integer’s results underscore the resilience and dynamism of the medical device contract manufacturing sector. The strong cardiovascular demand, robust order pipelines, and ability to pass through tariff costs reflect an industry benefiting from innovation cycles and non-elective therapy demand. OEMs and other contract manufacturers with global, vertically integrated footprints and targeted M&A roadmaps are best positioned to capture above-market growth and margin expansion. The muted impact of tariffs and ongoing outsourcing trends signal that supply chain flexibility and capability breadth remain critical differentiators as medtech customers pursue speed to market and cost efficiency. Investors should watch for similar dynamics and margin leverage across the broader medtech manufacturing value chain.

ITGR Healthcare Medical Devices OEM Manufacturing Cardiovascular Acquisitions Margin Expansion Tariffs